{"id":"vehicle-topical-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It provides a base for the active ingredients to adhere to the skin, allowing for localized delivery and potentially reducing systemic side effects. The exact mechanism of action depends on the active ingredients being delivered.","oneSentence":"Vehicle Topical Gel is a topical formulation that serves as a vehicle for delivering active pharmaceutical ingredients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:45.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various skin conditions"}]},"trialDetails":[{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT07437586","phase":"PHASE2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)","enrollment":60},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT05005845","phase":"PHASE2","title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","status":"COMPLETED","sponsor":"NFlection Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Cutaneous Neurofibroma, Neurofibromatosis 1","enrollment":199},{"nctId":"NCT06594393","phase":"PHASE2","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","status":"RECRUITING","sponsor":"Xinnate AB","startDate":"2026-01-30","conditions":"Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT07357870","phase":"PHASE1","title":"A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo","status":"RECRUITING","sponsor":"CAGE Bio Inc.","startDate":"2025-07-25","conditions":"Vitiligo","enrollment":36},{"nctId":"NCT06393452","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA","status":"COMPLETED","sponsor":"Pelage Pharmaceuticals, Inc.","startDate":"2024-06-05","conditions":"Androgenetic Alopecia","enrollment":78},{"nctId":"NCT03997851","phase":"PHASE1, PHASE2","title":"Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects","status":"COMPLETED","sponsor":"University of Miami","startDate":"2019-07-22","conditions":"Pruritus","enrollment":17},{"nctId":"NCT07244887","phase":"PHASE4","title":"Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris","status":"ENROLLING_BY_INVITATION","sponsor":"Oya Helin Dundar","startDate":"2025-06-17","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":"Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I","enrollment":18},{"nctId":"NCT06262607","phase":"PHASE2","title":"A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica","status":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","startDate":"2024-01-29","conditions":"Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)","enrollment":59},{"nctId":"NCT06050122","phase":"PHASE3","title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2024-03-17","conditions":"Gorlin Syndrome","enrollment":140},{"nctId":"NCT05930210","phase":"PHASE3","title":"A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer","status":"RECRUITING","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2023-05-30","conditions":"Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus","enrollment":230},{"nctId":"NCT07192588","phase":"PHASE2","title":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Graegis Pharmaceuticals Ltd","startDate":"2024-07-26","conditions":"Radiodermatitis; Acute","enrollment":273},{"nctId":"NCT06493578","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vyne Therapeutics Inc.","startDate":"2024-06-04","conditions":"Non-segmental Vitiligo","enrollment":200},{"nctId":"NCT05240300","phase":"PHASE1, PHASE2","title":"A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis","status":"WITHDRAWN","sponsor":"BiomX, Inc.","startDate":"2022-05","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT05639933","phase":"PHASE2","title":"Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors","status":"RECRUITING","sponsor":"Hoth Therapeutics, Inc.","startDate":"2023-07-19","conditions":"Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia","enrollment":152},{"nctId":"NCT04937920","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor","status":"COMPLETED","sponsor":"DermBiont, Inc.","startDate":"2021-03-16","conditions":"Tinea Versicolor","enrollment":34},{"nctId":"NCT06645509","phase":"PHASE2","title":"Severe Primary Hand Hyperhidrosis Treatment With Topical Administration of Victorhy","status":"TERMINATED","sponsor":"Dryox Health","startDate":"2024-04-29","conditions":"Palmar Hyperhidrosis","enrollment":58},{"nctId":"NCT05870865","phase":"PHASE2","title":"A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Formation Bio, Inc.","startDate":"2023-05-03","conditions":"Dermatitis, Atopic, Pruritus","enrollment":144},{"nctId":"NCT06969495","phase":"NA","title":"Pilot Clinical Study Testing Tiger Milk Mushroom Gel (Lignosus Rhinocerus TM02®) for Treating Mouth Ulcers","status":"COMPLETED","sponsor":"Mahsa University","startDate":"2023-02-01","conditions":"Mouth Ulcer","enrollment":21},{"nctId":"NCT03990051","phase":"PHASE2","title":"Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.","status":"COMPLETED","sponsor":"Glia, LLC","startDate":"2019-10-17","conditions":"Chronic Ocular Graft-versus-host Disease","enrollment":33},{"nctId":"NCT06945393","phase":"","title":"ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHT","status":"COMPLETED","sponsor":"L'Oreal","startDate":"2021-10-21","conditions":"Visible Light Exposure on Healthy Back Skin","enrollment":30},{"nctId":"NCT01963793","phase":"PHASE2","title":"Topical Aprepitant in Prurigo Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-10","conditions":"Pruritus","enrollment":20},{"nctId":"NCT01461655","phase":"PHASE2","title":"Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-11","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT01600014","phase":"PHASE3","title":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Actinic Keratosis","enrollment":463},{"nctId":"NCT01837576","phase":"PHASE1","title":"An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT06444594","phase":"EARLY_PHASE1","title":"Transient Receptor Potential Channels","status":"RECRUITING","sponsor":"Penn State University","startDate":"2024-07-17","conditions":"Aging","enrollment":45},{"nctId":"NCT05715346","phase":"PHASE1, PHASE2","title":"LEV102 Topical Gel in Acquired Blepharoptosis","status":"COMPLETED","sponsor":"Levation Pharma, Ltd.","startDate":"2023-02-23","conditions":"Acquired Blepharoptosis","enrollment":33},{"nctId":"NCT06673641","phase":"PHASE1","title":"A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-05-13","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT06380907","phase":"PHASE2","title":"A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis","status":"RECRUITING","sponsor":"Zai Lab (Hong Kong), Ltd.","startDate":"2024-05-22","conditions":"Plaque Psoriasis","enrollment":250},{"nctId":"NCT04893486","phase":"PHASE2","title":"CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2021-05-06","conditions":"BCCs in Gorlin Syndrome Patients","enrollment":73},{"nctId":"NCT03703310","phase":"PHASE3","title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2019-02-19","conditions":"Basal Cell Nevus Syndrome","enrollment":174},{"nctId":"NCT05007808","phase":"PHASE2","title":"Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee","status":"COMPLETED","sponsor":"BUZZZ Pharmaceuticals Limited","startDate":"2021-01-06","conditions":"Osteoarthritis, Knee","enrollment":210},{"nctId":"NCT00422240","phase":"PHASE3","title":"Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-06-27","conditions":"Acne Vulgaris","enrollment":1668},{"nctId":"NCT03094403","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-01","conditions":"Rosacea","enrollment":1000},{"nctId":"NCT05536882","phase":"PHASE3","title":"MC RCT - BPO vs Adapalene","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2022-05-18","conditions":"Molluscum Contagiosum","enrollment":""},{"nctId":"NCT04078555","phase":"PHASE2","title":"A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer","status":"UNKNOWN","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2022-07-26","conditions":"Venous Leg Ulcer","enrollment":80},{"nctId":"NCT05511948","phase":"PHASE2","title":"Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos","status":"COMPLETED","sponsor":"DermBiont, Inc.","startDate":"2022-08-18","conditions":"Hyperpigmentation","enrollment":75},{"nctId":"NCT03259620","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2017-10-30","conditions":"Cutaneous Common Warts","enrollment":491},{"nctId":"NCT02971891","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2017-01","conditions":"Cutaneous Common Warts","enrollment":484},{"nctId":"NCT01796795","phase":"PHASE2","title":"Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients","status":"SUSPENDED","sponsor":"G&E Herbal Biotechnology Co., LTD","startDate":"2030-09","conditions":"Common Wart","enrollment":102},{"nctId":"NCT04942860","phase":"PHASE3","title":"The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo","status":"COMPLETED","sponsor":"Nicolaus Copernicus University","startDate":"2019-10-01","conditions":"Non-segmental Vitiligo","enrollment":25},{"nctId":"NCT05062070","phase":"PHASE1","title":"Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex","status":"COMPLETED","sponsor":"BioMendics, LLC","startDate":"2022-05-05","conditions":"Epidermolysis Bullosa Simplex","enrollment":6},{"nctId":"NCT04186559","phase":"PHASE2","title":"Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers","status":"UNKNOWN","sponsor":"Silk Road Therapies, Inc.","startDate":"2024-02","conditions":"Behcet Syndrome, Behcet Disease","enrollment":60},{"nctId":"NCT00408330","phase":"PHASE2","title":"A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2006-12","conditions":"Seborrheic Dermatitis on the Face","enrollment":48},{"nctId":"NCT00403949","phase":"PHASE2","title":"A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2006-11","conditions":"Perioral Dermatitis","enrollment":48},{"nctId":"NCT04155190","phase":"PHASE2","title":"An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC","status":"TERMINATED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2019-12-20","conditions":"Recurrent Basal Cell Carcinoma","enrollment":47},{"nctId":"NCT02682238","phase":"PHASE2","title":"A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis","status":"COMPLETED","sponsor":"Botanix Pharmaceuticals","startDate":"2016-03-08","conditions":"Hyperhidrosis","enrollment":50},{"nctId":"NCT02798120","phase":"PHASE3","title":"P3 Long Term Safety Study of Once Daily SB204 in Acne","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-05-12","conditions":"Acne Vulgaris","enrollment":601},{"nctId":"NCT03798561","phase":"PHASE1","title":"Study to Evaluate ASN008 Topical Gel (TG)","status":"COMPLETED","sponsor":"Asana BioSciences","startDate":"2019-01-14","conditions":"Dermatitis, Atopic, Pruritus, Dermatitis Eczema","enrollment":24},{"nctId":"NCT02462187","phase":"PHASE2","title":"Topical NVN1000 for the Treatment of External Genital and Perianal Warts","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2015-06-12","conditions":"Genital Warts, Perianal Warts","enrollment":108},{"nctId":"NCT04769648","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease","status":"UNKNOWN","sponsor":"Glia, LLC","startDate":"2021-04-15","conditions":"Ocular Graft-versus-host Disease","enrollment":44},{"nctId":"NCT02367690","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-01","conditions":"Diabetic Foot Ulcers","enrollment":""},{"nctId":"NCT04219358","phase":"PHASE1","title":"Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-03-23","conditions":"Actinic Cheilitis","enrollment":49},{"nctId":"NCT01659853","phase":"PHASE3","title":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-09","conditions":"Erythema, Rosacea","enrollment":70},{"nctId":"NCT03578029","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa","status":"TERMINATED","sponsor":"Lenus Therapeutics, LLC","startDate":"2019-05-22","conditions":"Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa","enrollment":4},{"nctId":"NCT04435665","phase":"PHASE2","title":"NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","status":"COMPLETED","sponsor":"NFlection Therapeutics, Inc.","startDate":"2020-08-21","conditions":"Neurofibromatosis 1, Cutaneous Neurofibroma","enrollment":48},{"nctId":"NCT04886739","phase":"PHASE2","title":"CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea","status":"COMPLETED","sponsor":"CAGE Bio Inc.","startDate":"2021-05-07","conditions":"Rosacea","enrollment":78},{"nctId":"NCT02547441","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2015-12","conditions":"Rosacea","enrollment":463},{"nctId":"NCT02576860","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2015-10","conditions":"Rosacea","enrollment":263},{"nctId":"NCT00528021","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2007-08","conditions":"Pediculus Humanus Capitis, Head Lice","enrollment":230},{"nctId":"NCT03172780","phase":"PHASE3","title":"A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee\"","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Private Limited","startDate":"2017-05-24","conditions":"Osteoarthritis, Knee","enrollment":1220},{"nctId":"NCT03813992","phase":"PHASE3","title":"Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction","status":"COMPLETED","sponsor":"Futura Medical Developments Ltd.","startDate":"2018-11-01","conditions":"Erectile Dysfunction","enrollment":1005},{"nctId":"NCT05164393","phase":"PHASE1, PHASE2","title":"Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK","status":"UNKNOWN","sponsor":"Coegin Pharma AB","startDate":"2021-11-02","conditions":"Actinic Keratoses","enrollment":60},{"nctId":"NCT03852459","phase":"PHASE2","title":"Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS","status":"COMPLETED","sponsor":"Aponia Laboratories, Inc.","startDate":"2018-01-12","conditions":"Pain, Acute","enrollment":251},{"nctId":"NCT03393494","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2017-12-13","conditions":"Acne Vulgaris","enrollment":825},{"nctId":"NCT01796665","phase":"PHASE3","title":"A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2012-02","conditions":"Acne","enrollment":1180},{"nctId":"NCT01138514","phase":"PHASE3","title":"Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":1555},{"nctId":"NCT04995354","phase":"PHASE2, PHASE3","title":"Efficacy of EGF-loaded Self Healing Gel in Treatment of Oral Mucositis","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-06-01","conditions":"Oral Mucositis","enrollment":90},{"nctId":"NCT03532776","phase":"PHASE3","title":"Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts","status":"COMPLETED","sponsor":"Dermax SA","startDate":"2018-04-20","conditions":"External Anogenital Warts","enrollment":466},{"nctId":"NCT01993446","phase":"PHASE2","title":"A Safety and Efficacy Study of DRM02 in Subjects With Rosacea","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2013-10","conditions":"Rosacea","enrollment":30},{"nctId":"NCT01993420","phase":"PHASE2","title":"A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2013-10","conditions":"Atopic Dermatitis","enrollment":21},{"nctId":"NCT02431052","phase":"PHASE2","title":"A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":420},{"nctId":"NCT01936324","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2013-08","conditions":"Acne Vulgaris","enrollment":114},{"nctId":"NCT01993433","phase":"PHASE2","title":"A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2013-10","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT04088357","phase":"PHASE2","title":"Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants","status":"COMPLETED","sponsor":"BioMendics, LLC","startDate":"2019-08-26","conditions":"Wound Healing","enrollment":72},{"nctId":"NCT02121002","phase":"PHASE3","title":"Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2014-04","conditions":"Osteoarthritis","enrollment":1176},{"nctId":"NCT01268527","phase":"PHASE2","title":"A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2010-03-15","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT01174030","phase":"PHASE2","title":"Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-08","conditions":"Rosacea","enrollment":269},{"nctId":"NCT01494467","phase":"PHASE3","title":"Phase 3 Papulopustular Rosacea Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-12","conditions":"Papulopustular Rosacea","enrollment":688},{"nctId":"NCT01355458","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-05","conditions":"Rosacea","enrollment":260},{"nctId":"NCT00421993","phase":"PHASE3","title":"A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-10","conditions":"Acne Vulgaris","enrollment":1670},{"nctId":"NCT00687908","phase":"PHASE3","title":"Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-11","conditions":"Acne","enrollment":243},{"nctId":"NCT01493687","phase":"PHASE3","title":"Phase 3 Papulopustular Rosacea Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-12","conditions":"Papulopustular Rosacea (PPR)","enrollment":683},{"nctId":"NCT00989014","phase":"PHASE2","title":"Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-09","conditions":"Erythematotelangiectatic Rosacea","enrollment":122},{"nctId":"NCT01138735","phase":"PHASE4","title":"Epiduo Pediatric Acne Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-06","conditions":"Acne","enrollment":285},{"nctId":"NCT00688064","phase":"PHASE3","title":"Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-08","conditions":"Severe Acne Vulgaris","enrollment":459},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT01014689","phase":"PHASE3","title":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":378},{"nctId":"NCT01474590","phase":"PHASE3","title":"Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-11","conditions":"Acne","enrollment":266},{"nctId":"NCT01355471","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-05","conditions":"Rosacea","enrollment":293},{"nctId":"NCT04163263","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Boston Pharmaceuticals","startDate":"2019-11-04","conditions":"Moderate to Severe Acne Vulgaris","enrollment":66},{"nctId":"NCT03522441","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Akorn, Inc.","startDate":"2018-04-27","conditions":"Acne Vulgaris","enrollment":1125},{"nctId":"NCT02393937","phase":"PHASE3","title":"A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea","status":"COMPLETED","sponsor":"bioRASI, LLC","startDate":"2015-02","conditions":"Papulopustular Rosacea, Erythematotelangiectatic Rosacea","enrollment":963},{"nctId":"NCT00884234","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-02","conditions":"Lateral Canthal Lines","enrollment":30},{"nctId":"NCT03630939","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Escalier Biosciences B.V.","startDate":"2018-08-09","conditions":"Psoriatic Plaque","enrollment":104},{"nctId":"NCT01962987","phase":"PHASE3","title":"A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2013-03","conditions":"Actinic Keratosis","enrollment":476}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle Gel","placebo","TolaSure Vehicle Gel","Vehicle"],"phase":"phase_3","status":"active","brandName":"Vehicle Topical Gel","genericName":"Vehicle Topical Gel","companyName":"Maruho Co., Ltd.","companyId":"maruho-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Topical Gel is a topical formulation that serves as a vehicle for delivering active pharmaceutical ingredients. Used for Treatment of various skin conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}